In This Article:
The United States market has experienced a positive trajectory, climbing 2.7% in the last 7 days and showing a 9.6% increase over the past year, with earnings forecasted to grow by 14% annually. In such an environment, identifying stocks that are potentially priced below their intrinsic value can be key for investors seeking opportunities that align with these promising growth trends.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Trade Desk (NasdaqGM:TTD) | $53.63 | $106.20 | 49.5% |
| Lantheus Holdings (NasdaqGM:LNTH) | $104.34 | $204.26 | 48.9% |
| First Bancorp (NasdaqGS:FBNC) | $40.46 | $79.05 | 48.8% |
| SharkNinja (NYSE:SN) | $80.50 | $160.80 | 49.9% |
| Curbline Properties (NYSE:CURB) | $22.89 | $45.17 | 49.3% |
| Tenable Holdings (NasdaqGS:TENB) | $30.57 | $60.24 | 49.3% |
| BigCommerce Holdings (NasdaqGM:BIGC) | $5.18 | $10.35 | 49.9% |
| Verra Mobility (NasdaqCM:VRRM) | $21.80 | $43.13 | 49.5% |
| CBIZ (NYSE:CBZ) | $68.10 | $133.65 | 49% |
| Roku (NasdaqGS:ROKU) | $68.18 | $135.82 | 49.8% |
Let's take a closer look at a couple of our picks from the screened companies.
Kiniksa Pharmaceuticals International
Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company that develops and commercializes novel therapies for diseases with unmet needs, focusing on cardiovascular indications globally, with a market cap of approximately $1.89 billion.
Operations: Kiniksa Pharmaceuticals International generates its revenue from developing and delivering therapeutic medicines, amounting to $481.17 million.
Estimated Discount To Fair Value: 38.6%
Kiniksa Pharmaceuticals International is trading at US$26.97, significantly below its estimated fair value of US$43.96, suggesting it may be undervalued based on cash flows. The company recently raised its 2025 revenue guidance to between US$590 million and US$605 million, reflecting strong financial performance with Q1 2025 revenue at US$137.79 million compared to US$79.86 million a year ago, and a net income turnaround from a loss of USD 17.7 million to an income of USD 8.54 million.
AngloGold Ashanti
Overview: AngloGold Ashanti plc is a gold mining company with operations across Africa, Australia, and the Americas, and it has a market cap of approximately $20.48 billion.